Navigating the Portal 18 December 2017 Version 1.0.

Slides:



Advertisements
Similar presentations
© 2013 Sri U-Thong Limited. All rights reserved. This presentation has been prepared by Sri U-Thong Limited and its holding company (collectively, “Sri.
Advertisements

CA ERwin r8 installing the application things you should know before installing your CA ERwin r8 Data modeling application.
Fundamental Analysis Workshop Series Session Seven – Case Study #1.
Innovations in Structured Products October 25, 2010 An Innovator’s Dilemma?
Works Cardholder Tutorial Initial Login, Transaction Review, & Reports.
Mercer’s Climate Change Research 2011 to 2015
An Equity Perspective Paul Malan Global Markets 21 January 2004.
Mike Zenker Barclays Capital Research (415) November 12, 2007
Anticipated 2008 Generic Launches JULY 2008 David Harding, API Intelligence, Thomson Reuters Source: FDA, NEWPORT HORIZON PREMIUM TM © THOMSON REUTERS.
PRODUCTIVITY – THE PICTURE FOR THE UK & THE WEST MIDLANDS SUSTAINING COMPETITIVENESS CONFERENCE – THE BELFRY RHYS HERBERT SENIOR ECONOMIST 6 JULY 2012.
MESSAGING IN THE MEDIA TOP 10 DRUGS BASED ON CREDIBILITY INDEX IN THE LITERATURE JOHN KNAPP, DIRECTOR OF ANALYTICS MAY 2009 Your use of these materials.
End User License Agreement Permission to use and redistribute this Document is granted, provided that (1) the below copyright notice appears in all copies.
Therapeutic area breakdown of lead projects in development for first launch in 2005 APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM ©
Permission to reprint or distribute any content from this presentation requires the prior written approval of Standard & Poor’s. Copyright © 2014 by Standard.
Paragraph IV Patent Challenges – As of July 1, 2008 JULY 2008 David Harding, API Intelligence, Thomson Reuters Source: FDA, NEWPORT HORIZON PREMIUM TM.
Dunedin Enterprise Investment Trust PLC General Meeting – October 2013, Voting Analysis.
Proportion of biotech-derived active substances in development for first launch 31st December APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE.
International Telecommunication Union New Delhi, India, December 2011 ITU Workshop on Standards and Intellectual Property Rights (IPR) Issues Philip.
Changing Databases This presentation gives a quick overview on how to change databases in Osprey.
Legal Disclaimers Accuracy Every effort is made to provide information that is accurate. However any information contained in this website or the “article.
Oracle Fusion Applications 11gR1 ( ) Functional Overview (L2) Manage Inbound Logistics (L3) Manage Receipts.
1 XIII: Electronic Resources Managing Trials and Evaluations.
Proportion of total R&D expenditure by therapeutic area in 2005 APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS Your.
Oracle Fusion Applications 11gR1 ( ) Functional Overview (L2) Manage Inbound Logistics (L3) Manage and Disposition Inventory Returns.
Global R&D expenditure, development times, global pharmaceutical sales and new molecular entity output MARCH 2008 SOURCE: CMR INTERNATIONAL.
Oracle Fusion Applications 11gR1 ( ) Functional Overview (L2) Manage Inbound Logistics (L3) Inspect Material.
1 SFX TotalCare: User Interface Configuration - A-Z List.
2005/2006 Expenditure on biotech derived entities had remained constant APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS.
1 SFX TotalCare: User Interface Configuration - SFX Menu.
Number of pharmaceutical patent applications and granted patents for 5 major patent issuing authorities JUNE 2008 SOURCE: DERWENT WORLD PATENTS.
Investec Asset Management Update on Asset Class Returns December 2015.
Regulatory approval times between submission and marketing authorization approval APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM.
Availability of High-Quality API for India, China and Rest of World MARCH 2008 David Harding, API Intelligence, Thomson Reuters Source: NEWPORT HORIZON.
Capital Markets Expectations
Oracle E-Business Suite R12.1 Accounts Receivables Essentials Partner Boot Camp Training Courseware.
End User License Agreement Permission to use and redistribute this Document is granted, provided that (1) the below copyright notice appears in all copies.
Allocation of R&D expenditure in 2005 between chemical entity and biological or biotech active substances APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE.
Suffolk County Council Securities Finance Date: 19 th January, 2009 Location: Ipswich.
-1- For Oracle employees and authorized partners only. Do not distribute to third parties. © 2009 Oracle Corporation – Proprietary and Confidential Oracle.
The economic outlook. 2 Greece Russia 3 The deflation-ghost.
Permission to reprint or distribute any content from this presentation requires the prior written approval of Standard & Poor’s. Copyright © 2011 Standard.
The secure site rendering issue (all navigation crushed together as a list at the top of the page) is a compatibility issue with Internet Explorer only.
ERES 2016: “Solvency II – Optimising regulatory capital required to be held against real estate assets. A Case Study” Charles Ostroumoff 10 th June, 2016.
Copyright © 2012, Oracle and/or its affiliates. All rights reserved. Oracle Proprietary and Confidential. 1.
STOCK OPTIONS MONTHLY REPORT
HRMS At India Infoline 2008.
Connectivity to bank and sample account structure
Receptacle Housings for M-Style Infinite Switches
technology in retirement savings
BIOLOGY / CHEMISTRY CITATIONS GROWTH
Selecting the right provider
Under-rated assets in an over-priced world
Automation in an XML Authoring Environment
Messaging in the Media TOP 10 AUDIENCES BY THERAPY AREA
Transparency: Exceptions
Self-Registration walk-through
Transaction Reporting: Sources
2006 Revenue continued to depend on a relatively small number of products APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON REUTERS.
, R&D expenditure showed 6% growth annually
2002–2006 Mid and Other sized companies continued to launch the majority of NMEs APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM © THOMSON.
Proportion of total R&D expenditure on alliances or joint ventures by stage of R&D in 2005 APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS PROGRAM.
Transaction Reporting: Exception Handling
Transparency Reporting: Status
% of the projects in development in the leading therapeutic areas were considered to have a novel mode of action APRIL 2007 SOURCE: CMR INTERNATIONAL.
Pipeline size of Major companies had grown at a steadier rate than that of smaller companies APRIL 2007 SOURCE: CMR INTERNATIONAL PERFORMANCE.
Development time for new molecular entities first launched onto the world market between MARCH 2008 SOURCE: CMR INTERNATIONAL PERFORMANCE METRICS.
Cycle times decreased in larger but not smaller, companies
Proportion of total R&D expenditure by function in 2005
FOCUS SFTR Version 01 – Updated in January 2019.
© 2013 Sri U-Thong Limited. All rights reserved
Presentation transcript:

Navigating the Portal 18 December 2017 Version 1.0

Navigation Sidebar Contact Us This guide covers the following aspects of the NEX Regulatory Reporting Portal… Navigation Sidebar Contact Us 6 November 2018 Confidential

Navigation Sidebar By default, the Sidebar is pinned to the page. The Sidebar can be hidden to increase page space by clicking the push-in icon. The hidden Sidebar can be viewed at any stage by clicking the 3-line icon. The Sidebar can then either be pinned back in place by clicking the push-pin or re-hidden by clicking the 3-lines. While temporarily visible, an alternative page can be selected to navigate to before deciding to hide or pin the Sidebar. The options available in the Sidebar depend on a User’s entitlements. Some options will have a sub-set of options, accessible by clicking the main option or the down arrow next to the main option. The current page will always be highlighted in turquoise. Users can click on a different page at any time. If they have been entering data, a prompt will show asking to confirm they wish to continue so data is not unexpectedly lost. 6 November 2018 Confidential

Contact Us For details of how to contact NEX Regulatory Reporting, please visit the ‘Contact Us’ page. 6 November 2018 Confidential

Thank you Should you have any questions, please contact abide Thank you Should you have any questions, please contact abide.operations@abide-financial.com All information contained herein (“Information”) is for informational purposes only, is confidential and is the intellectual property of NEX Group plc and/or one of its group companies (“NEX”). The Information is directed to Eligible Counterparties and Professional Customers only and is not intended for Retail Clients (as each term is defined by the rules of the Financial Conduct Authority ("FCA")) or equivalent in a relevant jurisdiction. This Information is not, and should not be construed as, an offer or solicitation to sell or buy any product, investment, security or any other financial instrument or to participate in any particular trading strategy. The Information is not to be relied upon and is not warranted, either expressly or by implication, as to completeness, timeliness, accuracy, merchantability or fitness for any particular purpose. All representations and warranties are expressly disclaimed. Access to the Information by anyone other than the intended recipient is unauthorised and any disclosure, copying or redistribution is prohibited without NEX’s prior written approval. If you receive this information in error, please immediately delete all copies of it and notify the sender. In no circumstances will NEX be liable for any indirect or direct loss, or consequential loss or damages including without limitation, loss of business or profits arising from the use of, any inability to use, or any inaccuracy in the Information. NEX and the NEX logo are trademarks of the NEX group. Certain NEX group companies are regulated by regulatory authorities. For further regulatory information, please see www.nex.com. ©NEX Group plc 2017